Nasal microbiome

Development of a preparation based on polyvalent phages and compatible probiotics designed for the treatment and decolonization of the nasal cavity in inflammations caused by staphylococcal strains (specifically targeting the MRSA strain).

AUMED, a.s. has launched research focused on the preparation of a stable phage-probiotic product for the treatment of diseases caused by pathogenic strains of Staphylococcus aureus. Due to their high resistance to current antimicrobial agents, infections caused by these bacteria represent a significant challenge in treatment, prolong hospitalizations, and are among the primary causes of fatal nosocomial (hospital-acquired) infections worldwide.

WHY RESEARCH IN THIS AREA?

Research in this field is critical due to the rising resistance of Staphylococcus aureus bacteria (especially the MRSA strain) to common antibiotics, making them one of the leading causes of fatal hospital infections. Colonization of the nasal cavity by these pathogens is often asymptomatic; however, in immunocompromised patients or individuals post-surgery, it can lead to life-threatening conditions such as septic shock or pneumonia. As current treatments fail and lead to prolonged hospital stays, it is essential to develop an alternative, targeted therapy. The proposed solution, utilizing polyvalent phages in combination with probiotics, represents an innovative method to eliminate pathogens while simultaneously stabilizing the nasal microbiome—a product that is currently entirely absent from the EU market.

In addition to its therapeutic value, research in this area carries significant preventive and economic importance. The product, in the form of a spray or an insert, will enable effective decolonization not only in patients but also in high-risk carriers among healthcare personnel, thereby preventing the further spread of infection within the community. By utilizing natural bacterial viruses and beneficial bacteria, this method offers a safe treatment without adverse side effects. Ultimately, the research aims to significantly increase the efficiency of patient care and achieve substantial healthcare cost savings by shortening treatment duration and reducing the number of complicated cases.

AIM OF OUR RESEARCH

The outcome of these research activities should be a product in the form of a spray or an insert that ensures the gentle elimination of pathogenic bacteria and the subsequent stabilization of the nasal microbiome. This will provide a long-awaited therapeutic and preventive solution for both patients and healthcare personnel on the EU market.

The research is also carried out with the support of the Operational Programme Technologies and Applications for Competitiveness 2021-2027, Applications – DEEP TECH – Call III, registration number CZ.01.01.01/01/24_063/0006738.